Semin Vasc Med 2003; 03(3): 339-344
DOI: 10.1055/s-2003-44470
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Oral Anticoagulant Therapy in Patients with Peripheral Artery Disease

F. L.J. Visseren1 , B. C. Eikelboom2
  • 1Department of Internal and Vascular Medicine, University Medical Center Utrecht, The Netherlands;
  • 2Department of Vascular Surgery, University Medical Center Utrecht, The Netherlands
Further Information

Publication History

Publication Date:
21 November 2003 (online)

ABSTRACT

Patients with peripheral artery disease suffer from a high incidence of ischemic vascular complications in coronary, cerebral, and peripheral vascular beds. Reduction of atherothrombotic complications with aspirin or clopidogrel has proven to be successful. The role of oral anticoagulants in patients with symptomatic peripheral artery is limited. Randomized controlled trials comparing the effects of aspirin with oral anticoagulants are scarce. Oral anticoagulants (International Normalized Ratio = 2.5 to 4.5) are more effective than aspirin in preventing infrainguinal bypass occlusion only when venous graft material is used and the bypass is considered to be at high risk for occlusion. Whether the use of oral anticoagulants reduces all-cause morbidity and mortality is not unequivocally clear. The risk of ischemic events is reduced at the expense of an increased number of bleeding complications, which is one of the main reasons that therapy has not been widely adopted.

REFERENCES

  • 1 Leng G C, Fowkes F GR, Lee A J, Dunbar J, Housley E, Ruckley C V. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.  Br Med J . 1996;  313 1440-1444
  • 2 Criqui M H, Langer M D, Fronek A. et al . Mortality over a period of 10 years in patients with peripheral arterial disease.  N Engl J Med . 1992;  326 381-386
  • 3 Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen K H, Schroeder T. Fate in intermittent claudication: outcome and risk factors.  Br Med J . 1986;  293 1137-1140
  • 4 Donnelly R, Yeung J M. Management of intermittent claudication: the importance of secondary prevention.  Eur J Vasc Endovasc Surg . 2002;  23 100-107
  • 5 Pedersen T R, Kjekshus J, Pyorala K. et al . Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).  Am J Cardiol . 1998;  81 333-335
  • 6 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet . 2002;  360 7-22
  • 7 Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication.  Cochrane Database Syst Rev . 2001;  3 CD001999
  • 8 Dettori A G, Pini M, Moratti A. et al . Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. The APIC Study Group.  Angiology . 1989;  40 237-248
  • 9 De Smit P, van Urk H. Dutch oral anticoagulation trial.  Act Chir Austr . 1992;  24 5-7
  • 10 Antithrombotic Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients.  Br Med J . 1994;  308 81-106
  • 11 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis or randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  Br Med J . 2002;  324 71-86
  • 12 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet . 1996;  348 1329-1339
  • 13 Blaisdell F W, Steele M, Allen R E. Management of acute lower extremity arterial ischemia due to embolism and thrombosis.  Surgery . 1978;  84 822-834
  • 14 Tasc Working Group. Management of peripheral arterial disease (PAD).  J Vasc Surg . 2000;  31 s205-s226
  • 15 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy II. Maintenance of vascular graft or arterial patency by antiplatelet therapy.  Br Med J . 1994;  308 159-168
  • 16 The Femoro-Popliteal Bypass Trial Participants. Aspirin usage and its influence on femoro-popliteal vein graft patency.  Eur J Vasc Surg . 1992;  6 185-188
  • 17 Kretschmer G, Herbst F, Prager M. et al . A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis.  Arch Surg . 1992;  127 1112-1115
  • 18 Kretschmer G, Wenzl E, Piza F. et al . The influence of anticoagulant treatment on the probability of function in femoro-popliteal vein bypass surgery: analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial.  Surgery . 1987;  102 453-459
  • 19 Kretschmer G, Wenzl E, Schemper M. et al . Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery.  Lancet . 1988;  I 797-799
  • 20 Dutch Bypass Oral Anticoagulants or Aspirin (BOA) study group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral anticoagulants or Aspirin study): a randomised trial.  Lancet . 2000;  355 346-351
  • 21 Johnson W C, Williford W O. members of the Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomised study.  J Vasc Surg . 2002;  35 413-421
  • 22 Arfvidson B, Lundgren F, Drott C, Schersen T, Lundholm K. Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery.  Am J Surg . 1990;  159 556-560
  • 23 Sarac T P, Huber T S, Back M R, Ozaki C K, Carlton L M, Flynn T C, Seeger J M. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure.  J Vasc Surg . 1998;  28 446-457
  • 24 Schneider E, Brunner U, Bollinger A. Medikamentöse Rezidivprophylaxe nach femoropoplitealer Arterienrekonstruktion.  Angio . 1979;  2 73-77
    >